Acupuncture for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients with Stage I-III Breast Cancer

Inclusion Criteria

• History of histologically proven stage I-III breast cancer, without evidence of distant metastasis
• Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (with or without HER-2 directed therapy or with or without immunotherapy). Patient must enroll before the second infusion of a taxane
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Informed consent (signed or verbal, per participant preference)

Exclusion Criteria

• Previous receipt of CIPN-inducing chemotherapy agents (1 prior dose of a taxane is allowed)
• Unstable cardiac disease or myocardial infarction within 6 months prior to study entry
• Wearing a pacemaker or implantable cardioverter-defibrillator
• Uncontrolled seizure disorder
• History of pre-existing peripheral neuropathy
• Use of acupuncture within the 3 months prior to study enrollment
• Self-report of any CIPN symptoms via staff-administered Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PROCTCAE) CIPN, defined as either: * Report of “mild”, “moderate”, “severe”, “very severe” on the Severity Item on PRO-CTCAE CIPN assessment * Report of “a little bit”, “somewhat”, “quite a bit”, “very much” on the Interfere Item on PRO-CTCAE CIPN assessment